Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unequal CAB count means US delay on MRA (mutual recognition agreement):

This article was originally published in Clinica

Executive Summary

Following a long silence on the mutual recognition agreement(MRA) between the EU and the US, which most observers had expected would be officially adopted by now, it now seems that more observed audits will need to take place in the US before full implementation can take place. Indications are that the US now wants to ensure that it has as many conformity assessment bodies as the EU (currently it has three, compared to six in the EU). The speed at which the CABs can be recognised as ready for listing will depend on industry's willingness to invite potential conformity assessment bodies based in the US to take part in observed audits. In the past, companies were slow to put themselves forward and it is unclear what the situation is now.

You may also be interested in...



Volume-Based Purchasing Looms Larger In Post-Coronavirus China

China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.

Deals In Depth: February 2020

Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.

Notified Body Expert Akra Calls For Special Taskforce Measures To Oversee New COVID-19 Products

With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.

Topics

UsernamePublicRestriction

Register

MT060162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel